Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. Lin TS, et al. Among authors: stock w. Leuk Lymphoma. 2009 Dec;50(12):1958-63. doi: 10.3109/10428190903186486. Leuk Lymphoma. 2009. PMID: 19860603 Free PMC article. Clinical Trial.
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. Marcucci G, et al. Among authors: stock w. Ann Hematol. 2004;83 Suppl 1:S93-4. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124691 Clinical Trial. No abstract available.
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Marcucci G, et al. Among authors: stock w. J Clin Oncol. 2005 May 20;23(15):3404-11. doi: 10.1200/JCO.2005.09.118. Epub 2005 Apr 11. J Clin Oncol. 2005. PMID: 15824414 Clinical Trial.
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Gordon MK, et al. Among authors: stock w. Leuk Lymphoma. 2008 Mar;49(3):531-7. doi: 10.1080/10428190701799043. Leuk Lymphoma. 2008. PMID: 18297531
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. Klisovic RB, et al. Among authors: stock w. Clin Cancer Res. 2008 Apr 15;14(8):2444-9. doi: 10.1158/1078-0432.CCR-07-1320. Clin Cancer Res. 2008. PMID: 18413836 Clinical Trial.
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. Stock W, et al. Invest New Drugs. 2008 Aug;26(4):331-8. doi: 10.1007/s10637-008-9129-0. Epub 2008 Apr 19. Invest New Drugs. 2008. PMID: 18425419 Free PMC article. Clinical Trial.
612 results